We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market ...

The latest increase reflects the revival of the once-withdrawn antibody-drug conjugate Blenrep, as well as “multiple launch opportunities in the ’26-to-’31 period,” GSK CEO Emma Walmsley ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The company plans five new product approvals in 2025, including Blenrep for multiple myeloma and depemokimab for severe asthma. Specialty medicines accounted for more than 80% of GSK's growth in ...

These include depemokimab for severe asthma and Blenrep for multiple myeloma. Overall, GSK ranks 6th on our list of best immunology stocks to buy now. While we acknowledge the potential of GSK as ...

Pfizer's shot is also approved as a two-dose series administered six months apart. With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes The ACIP has already ...

GSK's 2024 results are strong, with a promising shift toward specialty medicines, particularly in HIV, respiratory conditions, and cancer, driving long-term growth. Key drugs Blenrep and ...

This year, GSK expects five product approvals, including the relaunch of blood cancer drug Blenrep, which it estimates could eventually reach annual sales of more than 3 billion pounds.

GSK said it now expects 2031 sales of $50 billion ... including plans for additional uses of its cancer drug Blenrep.

Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter ... The increase reflects the inclusion of Blenrep, the significant phase 3 progress since last year and multiple launch opportunities in ...